Diametric Capital’s Royalty Pharma RPRX Stock Holding History

Diametric Capital’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-11,851	Closed	-$360K	–	457
2024 Q1	$360K	Buy	+11,851	New	+$349K	0.2%	131

Other funds holding RPRX

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Diametric Capital's RPRX Position: Q2 2024 in Review

Diametric Capital sold out of Royalty Pharma (RPRX) in Q2 2024, closing a stake of 11,851 shares — an estimated $360K sold.

Diametric Capital first reported a position in RPRX in Q1 2024 and held it in 1 quarter. The position peaked at $360K in Q1 2024. 378 funds tracked by Wall St. Rank hold RPRX as of Q2 2024.

Diametric Capital reported no remaining Royalty Pharma position as of Q2 2024 after selling out during the quarter.
Diametric Capital sold 11,851 Royalty Pharma shares in Q2 2024, an estimated $360K.
Diametric Capital first reported a position in Royalty Pharma in Q1 2024 and held it in 1 quarter.
Diametric Capital's Royalty Pharma position peaked at $360K in Q1 2024.
378 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2024.

Based on Diametric Capital's 13F filing for Q2 2024, filed 13 Aug 2024.